title: Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression.
abstract: We report the case of a patient with subacute cerebellar degeneration presenting as paraneoplastic syndrome, preceding the final diagnosis of breast cancer. The tumor had high HER2 overexpression, so a weekly regimen of paclitaxel/trastuzumab was started after surgery of the primary breast tumor. Negativity of specific antineuronal antibodies and clinical stabilization of the patient was achieved after 12 cycles of treatment. The interest of this case is the unusual presentation and the targeted therapeutic approach that has been used.
authors.affiliation: Servicio de Oncologia Medica, Hospital Universitario Juan Canalejo-Maritimo de Oza, La Coruna, Spain. isagalls@yahoo.es
authors.forename: M Isabel Gallegos
authors.initials: MI
authors.lastname: Sancho
authors.forename: M Reboredo
authors.initials: MR
authors.lastname: Lopez
authors.forename: L Calvo
authors.initials: LC
authors.lastname: Martinez
authors.forename: R Garcia
authors.initials: RG
authors.lastname: Campelo
authors.forename: M S Lopez
authors.initials: MS
authors.lastname: Facal
authors.forename: B Sanroman
authors.initials: BS
authors.lastname: Budino
authors.forename: M Quindos
authors.initials: MQ
authors.lastname: Varela
authors.forename: S Antolin
authors.initials: SA
authors.lastname: Novoa
authors.forename: M Valladares
authors.initials: MV
authors.lastname: Ayerbes
authors.forename: G Alonso
authors.initials: GA
authors.lastname: Curbera
authors.forename: L M Anton
authors.initials: LM
authors.lastname: Aparicio
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000188:drug therapy; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D020362:Paraneoplastic Cerebellar Degeneration / Q000175:diagnosis* / Q000188:drug therapy; D049268:Positron-Emission Tomography; D017698:Postmenopause; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D018570:Risk Assessment; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab